Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Article content

• Collaboration to include clinical development, regulatory registration and commercialization in Japan ¹⁷⁷LO-PSMA-I&T and ⁶⁴Copper-PSMA-I&T
• It is based on a long-term relationship between the two companies
• About 90,000 new cases of prostate cancer are diagnosed in Japan every year

PARIS, Oct. 01, 2024 (GLOBE NEWSWIRE) — Curium, a global leader in nuclear medicine, today announced that it has entered into a strategic partnership with PDRadiopharma Inc., a wholly-owned subsidiary of PeptiDream, for clinical development and regulatory filing. , and marketed in Japan ¹⁷⁷LO-PSMA-I&T and ⁶⁴Copper-PSMA-I&T. The two agents ¹⁷⁷LO-PSMA-I&T and ⁶⁴Cu-PSMA-I&T targets prostate-specific membrane antigen (PSMA) expressed in prostate cancer cells and is being investigated for the treatment and diagnosis of prostate cancer. Both target tumors have high levels of PSMA expression and therefore potentially form a therapeutic pair (therapeutic and diagnostic).

Article content

Under the terms of the partnership, Curium and PDRadiopharma will jointly collaborate on clinical development activities ¹⁷⁷LO-PSMA-I&T and ⁶⁴Cu-PSMA-I&T in Japan, with PDRadiopharma leading regulatory filing, manufacturing, marketing and distribution activities in Japan. Corium will continue to lead global personnel development and support PDRadiopharma through technology transfer to support the establishment of manufacturing lines in Japan – including a high-throughput Copper 64 manufacturing line based on Corium’s proprietary technology.

Patrick C. Reed, President and CEO of PeptiDream, commented: “Targeted radiopharmaceuticals are rapidly revolutionizing how we diagnose and treat cancer. At PeptiDream and PDRadiopharma, we are focused on expanding our pipeline of these powerful targeted therapies, and we are thrilled to be able to accelerate these efforts by partnering with Curium to bring these highly promising radiopharmaceuticals to prostate cancer.” Which targets patients in Japan.

Masato Murakami, President of PDRadiopharma and Chief Marketing Officer of PeptiDream, commented: “We are excited to partner with Curium in developing ¹⁷⁷LO-PSMA-I&T and ⁶⁴Cu-PSMA-I&T, a very promising product for the diagnosis and treatment of PSMA-expressing prostate cancer. We look forward to working with Curium to deliver these much-needed agents to prostate cancer patients in Japan as quickly as possible.”

Article content

Article content

Chaitanya Tataneni, CEO, International Markets, Corium, commented: “As a global radiopharmaceutical innovator with a promising late-stage oncology pipeline, Curium is pleased to collaborate with PDRadiopharma, which has more than four decades of experience in Japan. Both Curium and PDRadiopharma plan to leverage their complementary strengths to accelerate the development of Innovative products for prostate cancer patients in Japan.

Prostate cancer remains widespread in Japan. Annually, there are approximately 90,000 to 100,000 new cases. Patients with metastatic castration-resistant prostate cancer have a survival rate of about three years in clinical trial settings, and even less in the real world, and a significant amount of medical care remains untreated. Satisfied. The need for treatments.

¹⁷⁷Lu-PSMA-I&T, a PSMA inhibitor conjugated to the radioisotope lutetium 177, is currently being tested by Curium in a global pivotal phase 3 ECLIPSE trial (ClinicalTrials.gov identifier; NCT05204927). ECLIPSE is a multicenter, open-label, randomized clinical trial comparing safety and efficacy ¹⁷⁷Lu-PSMA-I&T versus hormonal therapy in patients with metastatic castration-resistant prostate cancer. The ECLIPSE trial has enrolled more than 400 patients at 51 trial sites in the United States and Europe.

Article content

⁶⁴Cu-PSMA-I&T PET is currently being studied in two multicenter phase III trials; The SOLAR RECUR test for diagnostic performance in men with a biochemical recurrence of prostate cancer (ClinicalTrials.gov identifier NCT06235099) and the SOLAR STAGE test for diagnostic performance in men with newly diagnosed unfavorable intermediate- to high-risk prostate cancer (ClinicalTrials.gov identifier; NCT06235151 ). The first in the human Phase 1/2 SOLAR trial met the co-primary endpoints of region-level correct localization rate and patient-level correct detection rate in patients with histologically proven metastatic prostate cancer. PSMA-targeted positron emission tomography/CT is increasingly emerging as a highly sensitive method for detecting locally recurrent or metastatic lesions in the context of biochemical recurrence and for localizing primary prostate cancer.

There is a long-standing relationship between Curium and PDRadiopharma in the field of radiopharmaceuticals.

For more information:

Baby Dream Company
Yuko Okimoto, Investor Relations and Public Affairs
info@peptidream.com

Article content

B Radio Pharma Company
Noriko Tanaka, Public Affairs
s-info-hq@pradiopharma.com

Curium
Ross Bethell
Vice President, Head of Global Communications
communication@curiumpharma.com

About PeptiDream Inc.
PeptiDream Inc. (TSE No. 4587) is leading the translation of macrocyclic peptides into an entirely new class of innovative medicines to address unmet medical needs and improve the quality of life of patients around the world. In its radiopharmaceuticals business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of radiopharmaceuticals and radiodiagnostics approved in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep portfolio One of the innovative products. Targeted radiation therapy and diagnostics, which includes both wholly-owned in-house programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream similarly leverages PDPS to discover and develop a broad and diversified portfolio of investigational peptide therapeutics, peptide drug conjugates (PDC) and multifunctional peptide conjugates (MPC) through an extensive global discovery and development network. partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipelines, please visit the website www.peptidream.com/en

Article content

About BRadiopharma
PDRadiopharma, a wholly-owned subsidiary of PeptiDream since 2022, has been providing high-quality radiopharmaceuticals through R&D, manufacturing, regulation and sales as a leading radiopharmaceutical company, since it started its business in 1968. PDRadiopharma currently markets 21 products For radiodiagnosis (including SPECT and PET products) and 8 radiotherapy products (3 product categories) in Japan. In addition, PDRadiopharma and PeptiDream are developing a wide range of radiotherapies and radiodiagnostics for both Japanese and global markets. For more information about PDRadiopharma, please visit the website www.pradiopharma.com/en

About curium
Curium is a world leader in nuclear medicine. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the world. Our proven heritage combined with a pioneering approach are the hallmarks of delivering innovation, excellence and unparalleled service. With manufacturing facilities located throughout Europe and the United States, Curium provides SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to more than 14 million patients annually. The name “Curium” honors the legacy of pioneering radioactive materials researchers, Marie and Pierre Curie, after whom the radioactive element is named, and underscores our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

Article content